For research use only. Not for therapeutic Use.
KRM-III is a potent and orally active T-cell antigen receptor (TCR) inhibitor. KRM-III inhibits TCR- and phorbol myristate acetate/ionomycin-induced activation of nuclear factor of activated T cells (NFAT) and T-cell proliferation with an IC50 of ~5 μM. Anti-inflammatory activity[1].
| Catalog Number | I030164 |
| CAS Number | 79220-94-3 |
| Synonyms | 3,5-diphenyl-1H-imidazole-2-thione |
| Molecular Formula | C15H12N2S |
| Purity | ≥95% |
| InChI | InChI=1S/C15H12N2S/c18-15-16-14(12-7-3-1-4-8-12)11-17(15)13-9-5-2-6-10-13/h1-11H,(H,16,18) |
| InChIKey | QKOAQVKXZJFMET-UHFFFAOYSA-N |
| SMILES | C1=CC=C(C=C1)C2=CN(C(=S)N2)C3=CC=CC=C3 |
| Reference | [1]. Eun Joo Jung, et al. Oral administration of 1,4-aryl-2-mercaptoimidazole inhibits T-cell proliferation and reduces clinical severity in the murine experimental autoimmune encephalomyelitis model. J Pharmacol Exp Ther. 2009 Dec;331(3):1005-13. |
